An observational study in Stroke, Low-Density-Lipoprotein-cholesterol Level and Risk Factors, sponsored by Jordan Collaborating Cardiology Group. Not yet recruiting at 1 site in Jordan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by Jordan Collaborating Cardiology Group · Observational
Stroke is a well-known a leading cause of death and disability in the Middle East. There remain many knowledge gaps in evaluating the prevalence of risk factors among patients with stroke in the Middle East. Unravelling the impact of these risk factors and controlling them can positively lower the incidence of stroke. Disparities in stroke risk factors, may well be related to ethnicity of the Middle Eastern populations , will be compared with those among stroke patients in the western literature.
Stroke is a well-known a leading cause of death and disability in the Middle East. There remain many knowledge gaps in evaluating the prevalence of risk factors among patients with stroke in the Middle East. Unravelling the impact of these risk factors and controlling them can positively lower the incidence of stroke. Disparities in stroke risk factors, may well be related to ethnicity of the Middle Eastern populations , will be compared with those among stroke patients in the western literature.
These clinically relevant issues have not been studied extensively in the Middle East where most of the studies in atherosclerotic cardiovascular disease have focused on acute coronary syndrome more than stroke. Exploring new information on risk factors of stroke in this region that helps fill some of the knowledge gaps.
Stroke has been attributed, in the majority of cases, to the traditional four standard modifiable risk factors of hypertension, type 2 diabetes, dyslipidemia, and cigarette smoking. However, ethnicity and geography account for the interregional differences of the prevalence of risk factors in patients with stroke.
The Jo-SMMART ill evaluate risk factors in 2000 stroke patients in Jordan as a representative of the Middle Eastern population, the prevalence of those with none of the 4 risk factors and the differences in clinical profiles and demographic features on those with risk factors and those with no risk factors. Lipid profile and use of lipid lowering agents will also be evaluated, and furthermore the die0fferneces between young vs old, and men vs women stroke patients ill be addressed.
8,255 studies on the registry are indexed under Stroke; 2,056 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 152 across 1,968 observational studies indexed under Stroke.
Browse Stroke studies →Jordan Collaborating Cardiology Group is the lead sponsor of 26 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Will enroll adults admitted to the hospital with a working diagnosis of stroke and then the diagnosis is confirmed by a neurologist. Patients ii be interviewed for data collection of 4 risk factors as above in addition to the serum level of LDLC and the use of lipid lowering agents.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Prevalence of hypertension in stroke patients (survey interview)
BP more 140/90 or known diagnosis of high blood pressure or patient already on blood pressure medication
Time frame: Baseline
Prevalence of type 2 diabetes in stroke patients (survey interview)
HbA1c more than 6.5%, or known diagnosis of type 2 diabetes or patient already on anti diabetes medications
Time frame: BASELINE
Prevalence of elevated serum level of low density lipoprotein cholesterol in stroke patients (survey interview)
Elevated serum level of low density lipoprotein cholesterol \> 55 mg/dl or patient already on lipid lowering medication
Time frame: BASELINE
Prevalence of current cigarette smoking in stroke patients (survey interview)
Known current cigarette smoking of any number of cigarettes per day
Time frame: BASELINE
Use of lipid lowering therapy (survey interview)
Current use of statin, ezitimibe, PCS9 inhibitor of small interfering RNA agent to lower the LDL-C
Time frame: BASELINE
Plan to share: Yes — All individual participant data will be available in the form of excel sheet with no disclosure of patients names. Can be requested from the study director
No publications or documents are linked to this record.
Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jordan Collaborating Cardiology Group